Other OTC - Delayed Quote USD

Provectus Biopharmaceuticals, Inc. (PVCT)

0.1985 +0.0021 (+1.07%)
At close: April 26 at 3:50 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Edward V. Pershing CPA CEO & Chairman of Board 75k -- 1954
Mr. Dominic Rodrigues C.F.A., CFA President, Chief Operations Consultant & Vice Chairman of the Board 75k -- 1969
Dr. Eric A. Wachter Co-Founder & CTO 174.19k -- 1963
Ms. Heather Raines CPA Chief Financial Officer 83.33k -- 1967

Provectus Biopharmaceuticals, Inc.

800 South Gay Street
Suite 1610
Knoxville, TN 37929
United States
866 594 5999 https://www.provectusbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4

Description

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Corporate Governance

Provectus Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
Provectus Biopharmaceuticals, Inc. Earnings Call

Related Tickers

CELUW Celularity Inc.
0.0255
0.00%
 
ENZN Enzon Pharmaceuticals, Inc.
0.0835
-5.17%
 
NYMXF Nymox Pharmaceutical Corporation
0.3000
0.00%
 
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%
 
FLUO.ST FluoGuide A/S
48.90
+7.47%
 
RNXT RenovoRx, Inc.
1.2430
+0.24%
 
GTBP GT Biopharma, Inc.
3.3450
-8.86%
 
PCVX Vaxcyte, Inc.
60.72
+1.10%
 
PPCB Propanc Biopharma, Inc.
0.0010
-9.09%
 
NNVC NanoViricides, Inc.
1.1000
-0.90%